Pre-Clinical and Research Vector Products

Overview

The Cincinnati Children's Hospital Medical Center Viral Vector Core at the Division of Experimental Hematology and Cancer Biology offers production of research-grade retroviral and lentiviral vectors, generation of stable producer lines, and non-GMP quality control testing including vector titer by functional assay FACS or PCR, mycoplasma, and sterility testing. To date, the research Viral Vector Core has provided over five thousand viral vector preps to 120 investigators at 21 institutions locally, nationally and internationally.

The Viral Vector Core has been listed as a shared resource of the Ohio State Comprehensive Cancer Center (OSUCCC)-Cincinnati Children's Cancer Consortium. Vector development is provided in collaboration with Dr. Axel Schambach and Prof. Dr. Christopher Baum, at the Department of Experimental Hematology at the Hannover Medical School in Hannover, Germany.

Service Requests

For non-GMP research-grade vector requests, use the link to the CORES Ordering System available on the left under "Vector Ordering". For larger orders, and for investigators outside of Cincinnati Children's, a production agreement may be required.  For vector for clinical application, please contact us for additional information.

When entering an order, CORES will first ask that you select the budget number to be used for the project. Please search for the last name of the PI and select the correct budget number from the list. If the budget number or PI name are not available, please click here for additional information (CCHMC only), or E-mail: help-cores@bmi.cchmc.org.

If you are a member of one of the p30 Centers of Excellence (Center of Excellence for Molecular Hematology, Digestive Health Center, and/or Cincinnati Rheumatic Disease Center) you will still receive your respective subsidy. The discount will not be applied in your emailed invoice.  However, each shared facility will be conducting a second cost transfer process with research accounting to apply your subsidies.  For services provided to investigators at outside institutions, fees include standard overhead charges.

Selected References

1. Arumugam PI, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P et al. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther 2009; 17(11): 1929-37.

2. Schambach A, Galla M, Maetzig T, Loew R, Baum C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15(6): 1167-73.

3. Schambach A, Bohne J, Baum C. Safety-modified versions of the woodchuck hepatitis virus posttranscriptional regulatory element for enhancement of retroviral vector titer and expression. 2005.

4. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101(6): 2099-114.